Kate Rosenbluth is co-founder and CEO of Cala Health, a medical technology company pioneering a new class of electrical medicine to treat chronic disease non-invasively by stimulating peripheral nerves with body-worn electronics. She has developed cutting-edge neurotherapies with Brainlab, Autonomic Technologies, and Genentech. She was a lecturer and fellow in Stanford Technology Ventures Program and Biodesign and a Postdoctoral Fellow in UCSF Neurosurgery. She is a committed educator and has launched forward-looking programs including the Masters of Translational Medicine at UC Berkeley and the Accel Innovation Scholars at Stanford. She serves on the Strategy Group of the Center for Healthcare Innovation and the McKinsey Women’s Executive Roundtable. Kate has authored more than 50 patents and peer-reviewed publications.